Incyte shares, UBS lifts price target after Opzelura opinion

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 12:13.

Incyte (US45337C1027) starts Saturday with a European medicines headline and a fresh broker call. UBS lifted its price target to 113 dollars on June 26 after the EU regulator's CHMP backed label expansion for Opzelura, according to MarketScreener and the company release.

UBS turns more constructive

MarketScreener's June 26 feed lists UBS at 113 dollars from 103 dollars, with a Neutral rating kept in place. The same page also records Incyte's June 26 announcement of a positive CHMP opinion for Opzelura cream in adult atopic dermatitis. MarketScreener's June 26 update

The opinion matters because it opens the way for a possible European Commission decision. Reuters-style market coverage on June 26 put the stock's move in the context of the EU review, with Opzelura at the center of the debate. Investing.com's report on the EU review

Consensus stays mixed

Analyst language around Incyte remains split. MarketBeat's June 27 filing roundup says Sanford C. Bernstein began coverage with Market Perform and a 99 dollar target, while Jefferies cut its view to Hold earlier this year, according to the same report. MarketBeat's June 27 analyst summary

The chart picture is firmer than the rating debate. StockScan shows Incyte at 113.75 dollars in after-hours trading, while CNBC on June 26 said the shares were moving out of a seven-month range and into a breakout setup. CNBC's June 26 chart note

Opzelura drives the story

Opzelura is Incyte's ruxolitinib cream, sold for dermatology use. The product is now the clearest Europe-facing asset in the portfolio after the positive CHMP opinion.

Nasdaq price snapshot

The Incyte shares (US45337C1027) trade on 2026-06-27, 12:13 on Nasdaq at 100.75 dollars.

Disclaimer: Market data can change during trading hours. This article is for information only and is not investment advice.